Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 4, 2013, Pages 449-452

  Kaneva, Kristiyana ^a   Bansal, Vinod ^b   Hoppensteadt, Debra ^a   Cunanan, Josephine ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulants; heparins; renal failure

Indexed keywords

ANTIBODY; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A ANTIBODY; HEPARIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CENTRAL VENOUS CATHETERIZATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPTEST; HUMAN; KIDNEY CLEARANCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBINASE INDUCED CLOTTING TIME; THROMBIN TIME;

ANTICOAGULANTS; HEPARINS; RENAL FAILURE;

ADULT; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 84879935406     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613479820     Document Type: Article

References (15)

1. Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. Semin Dial. 2010 ; 23 (5). 510-515
2. Ivan DM, Smith T, Allon M. Does the heparin lock concentration affect hemodialysis catheter patency?. Clin J Am Soc Nephrol. 2010 ; 5 (8). 1458-1462
3. Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int. 2011 ; 15 (suppl 1). S43 - S48
4. Sabry A, Taha M, Nada M, Al Fawzan F, Alsaran K. Anticoagulation therapy during hemodialysis: a comparative study between two heparin regimens. Blood Coagul Fibrinolysis. 2009 ; 20 (1). 57-62
5. Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes during hemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant. 2006 ; 21 (2). 444-449
6. Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009 ; 4 (9). 1459-1464
7. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP. Hemodialysis for patients bleeding or at risk for bleeding can be simple, safe and efficient. Clin Nephrol. 2004 ; 62 (1). 29-34
8. Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ. Heparin free dialysis: comparative data and results in high risk patients. Kidney Int. 1987 ; 31 (6). 1351-1355
9. Guillet B, Simon N, Sampol JJ, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in hemodialysis. Nephrol Dial Transplant. 2003 ; 18 (11). 2348-2355
10. Vareesangthip K, Thitiarchakul S, Kanjanakul I, et al. Efficacy and safety of enoxaparin during hemodialysis: results from the HENOX study. J Med Assoc Thai. 2011 ; 94 (1). 21-26
11. Hu HH, Hsu CY, Fang HC, et al. Low-dose heparin retention in temporary hemodialysis double-lumen catheter does not increase catheter occlusion and might reduce risk of bleeding. Blood Purif. 2011 ; 32 (3). 232-237
12. Brunet P, Simon N, Opris A, et al. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis. 2008 ; 51 (5). 789-795
13. Fourtounas C. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session: the impact of the administered dose. Am J Kidney Dis. 2008 ; 52 (4). 805-806
14. Shinoda T.. Anticoagulation in acute blood purification for acute renal failure in critical care. Contrib Nephrol. 2010 ; 166: 119-125
15. Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine (Baltimore). 1983 ; 62 (4). 209-220